MiRNA as prognostic and therapeutic targets in tumor of male urogenital tract

Molecular Targets and Strategies in Cancer Prevention

Volumn , Issue , 2016, Pages 151-171

  Caraglia, M ^a   Alaia, C ^a   Grimaldi, A ^a   Boccellino, M ^a   Quagliuolo, L ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Biogenesis; Biomarkers; Bladder cancer; MiRNA; Testicular cancer

Indexed keywords

EID: 85025836913     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-319-31254-5_7     Document Type: Chapter

References (107)

1. Pichler M, Calin GA. MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients. Br J Cancer. 2015;113:569-73.
2. Tagliaferri P, Rossi M, Di Martino MT, Amodio N, Leone E, et al. Promises and challenges of MicroRNA-based treatment of multiple myeloma. Curr Cancer Drug Targets. 2012;12:838-46.
3. Boccellino M, Alaia C, Misso G, Cossu AM, Facchini G, et al. Gene interference strategies as a new tool for the treatment of prostate cancer. Endocrine. 2015;49:588-605.
4. Purdue MP, Devesa SS, Sigurdson AJ, McGlynn KA. International patterns and trends in testis cancer incidence. Int J Cancer. 2005;115:822-7.
5. Chia VM, Quraishi SM, Devesa SS, Purdue MP, Cook MB, et al. International trends in the incidence of testicular cancer, 1973-2002. Cancer Epidemiol Biomarkers Prev. 2010;19:1151-9.
6. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-917.
7. Rosen A, Jayram G, Drazer M, Eggener SE. Global trends in testicular cancer incidence and mortality. Eur Urol. 2011;60:374-9.
8. Sagalowsky AI. Current considerations in the diagnosis and initial treatment of testicular cancer. Compr Ther. 1994;20:688-94.
9. Daniels Jr JL, Stutzman RE, McLeod DG. A comparison of testicular tumors in black and white patients. J Urol. 1981;125:341-2.
10. Moller H. Trends in incidence of testicular cancer and prostate cancer in Denmark. Hum Reprod. 2001;16:1007-11.
11. Moller H, Prener A, Skakkebaek NE. Testicular cancer, cryptorchidism, inguinal hernia, testicular atrophy, and genital malformations: case-control studies in Denmark. Cancer Causes Control. 1996;7:264-74.
12. Aguirre D, Nieto K, Lazos M, Pena YR, Palma I, et al. Extragonadal germ cell tumors are often associated with Klinefelter syndrome. Hum Pathol. 2006;37:477-80.
13. Dieckmann KP, Loy V. The value of the biopsy of the contralateral testis in patients with testicular germ cell cancer: the recent German experience. APMIS. 1998;106:13-20. discussion 20-13.
14. Eisenberg ML, Li S, Brooks JD, Cullen MR, Baker LC. Increased risk of cancer in infertile men: analysis of U.S. claims data. J Urol. 2015;193:1596-601.
15. Magoha GA. Testicular cancer in Nigerians. East Afr Med J. 1995;72:554-6.
16. Opot EN, Magoha GA. Testicular cancer at Kenyatta National Hospital, Nairobi. East Afr Med J. 2000;77:80-5.
17. Mitchell RT, Camacho-Moll E, Macdonald J, Anderson RA, Kelnar CJ, et al. Intratubular germ cell neoplasia of the human testis: heterogeneous protein expression and relation to invasive potential. Mod Pathol. 2014;27:1255-66.
18. Hoei-Hansen CE, Rajpert-De Meyts E, Daugaard G, Skakkebaek NE. Carcinoma in situ testis, the progenitor of testicular germ cell tumours: a clinical review. Ann Oncol. 2005;16:863-8.
19. Voorhoeve PM, le Sage C, Schrier M, Gillis AJ, Stoop H, et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Adv Exp Med Biol. 2007;604:17-46.
20. Spiekermann M, Dieckmann KP, Balks T, Bullerdiek J, Belge G. Is relative quantification dispensable for the measurement of microRNAs as serum biomarkers in germ cell tumors? Anticancer Res. 2015;35:117-21.
21. Bezan A, Gerger A, Pichler M. MicroRNAs in testicular cancer: implications for pathogenesis, diagnosis, prognosis and therapy. Anticancer Res. 2014;34:2709-13.
22. McIver SC, Roman SD, Nixon B, McLaughlin EA. miRNA and mammalian male germ cells. Hum Reprod Update. 2012;18:44-59.
23. McIver SC, Roman SD, Nixon B, Loveland KL, McLaughlin EA. The rise of testicular germ cell tumours: the search for causes, risk factors and novel therapeutic targets. F1000Res. 2013;2:55.
24. McIver SC, Stanger SJ, Santarelli DM, Roman SD, Nixon B, et al. A unique combination of male germ cell miRNAs coordinates gonocyte differentiation. PLoS One. 2012;7:e35553.
25. Di Vizio D, Cito L, Boccia A, ChieffiP, Insabato L, et al. Loss of the tumor suppressor gene PTEN marks the transition from intratubular germ cell neoplasias (ITGCN) to invasive germ cell tumors. Oncogene. 2005;24:1882-94.
26. Gilbert DC, McIntyre A, Summersgill B, Missiaglia E, Goddard NC, et al. Minimum regions of genomic imbalance in stage I testicular embryonal carcinoma and association of 22q loss with relapse. Genes Chromosomes Cancer. 2011;50:186-95.
27. Freemantle SJ, Vaseva AV, Ewings KE, Bee T, Krizan KA, et al. Repression of cyclin D1 as a target for germ cell tumors. Int J Oncol. 2007;30:333-40.
28. Gillis AJ, Stoop HJ, Hersmus R, Oosterhuis JW, Sun Y, et al. High-throughput microRNAome analysis in human germ cell tumours. J Pathol. 2007;213:319-28.
29. Syring I, Bartels J, Holdenrieder S, Kristiansen G, Muller SC, et al. Circulating serum miRNA (miR-367-3p, miR-371a-3p, miR-372-3p and miR-373-3p) as biomarkers in patients with testicular germ cell cancer. J Urol. 2015;193:331-7.
30. Novotny GW, Belling KC, Bramsen JB, Nielsen JE, Bork-Jensen J, et al. MicroRNA expression profiling of carcinoma in situ cells of the testis. Endocr Relat Cancer. 2012;19:365-79.
31. Zabolotneva AA, Zhavoronkov AA, Shegay PV, Gaifullin NM, Alekseev BY, et al. A systematic experimental evaluation of microRNA markers of human bladder cancer. Front Genet. 2013;4:247.
32. Puerta-Gil P, Garcia-Baquero R, Jia AY, Ocana S, Alvarez-Mugica M, et al. miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer. Am J Pathol. 2012;180:1808-15.
33. Zhang DQ, Zhou CK, Jiang XW, Chen J, Shi BK. Increased expression of miR-222 is associated with poor prognosis in bladder cancer. World J Surg Oncol. 2014;12:241.
34. Zhang DZ, Lau KM, Chan ES, Wang G, Szeto CC, et al. Cell-free urinary microRNA-99a and microRNA-125b are diagnostic markers for the non-invasive screening of bladder cancer. PLoS One. 2014;9:e100793.
35. Xu X, Chen H, Lin Y, Hu Z, Mao Y, et al. MicroRNA-409-3p inhibits migration and invasion of bladder cancer cells via targeting c-Met. Mol Cells. 2013;36:62-8.
36. Feng Y, Liu J, Kang Y, He Y, Liang B, et al. miR-19a acts as an oncogenic microRNA and is up-regulated in bladder cancer. J Exp Clin Cancer Res. 2014;33:67.
37. Ratert N, Meyer HA, Jung M, Lioudmer P, Mollenkopf HJ, et al. miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome. J Mol Diagn. 2013;15:695-705.
38. Mahdavinezhad A, Mousavibahar SH, Poorolajal J, Yadegarazari R, Jafari M, et al. Association between tissue miR-141, miR-200c and miR-30b and bladder cancer: a matched case-control study. Urol J. 2015;12:2010-3.
39. Kim SM, Kang HW, Kim WT, Kim YJ, Yun SJ, et al. Cell-free microRNA-214 from urine as a biomarker for non-muscle-invasive bladder cancer. Korean J Urol. 2013;54:791-6.
40. Dyrskjot L, Ostenfeld MS, Bramsen JB, Silahtaroglu AN, Lamy P, et al. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res. 2009;69:4851-60.
41. Ichimi T, Enokida H, Okuno Y, Kunimoto R, Chiyomaru T, et al. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer. 2009;125:345-52.
42. Yamada Y, Enokida H, Kojima S, Kawakami K, Chiyomaru T, et al. MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Cancer Sci. 2011;102:522-9.
43. Wang G, Chan ES, Kwan BC, Li PK, Yip SK, et al. Expression of microRNAs in the urine of patients with bladder cancer. Clin Genitourin Cancer. 2012;10:106-13.
44. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
45. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006;118:3030-44.
46. Bedwani R, Renganathan E, El Kwhsky F, Braga C, Abu Seif HH, et al. Schistosomiasis and the risk of bladder cancer in Alexandria, Egypt. Br J Cancer. 1998;77:1186-9.
47. Rosin MP, Saad el Din Zaki S, Ward AJ, Anwar WA. Involvement of inflammatory reactions and elevated cell proliferation in the development of bladder cancer in schistosomiasis patients. Mutat Res. 1994;305:283-92.
48. Weitzman SA, Stossel TP. Mutation caused by human phagocytes. Science. 1981;212: 546-7.
49. Weitberg AB. Effect of combinations of antioxidants on phagocyte-induced sister-chromatid exchanges. Mutat Res. 1989;224:1-4.
50. O’Brien PJ. Radical formation during the peroxidase catalyzed metabolism of carcinogens and xenobiotics: the reactivity of these radicals with GSH, DNA, and unsaturated lipid. Free Radic Biol Med. 1988;4:169-83.
51. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, et al. A review of human carcinogens Part B: biological agents. Lancet Oncol. 2009;10:321-2.
52. Galsky MD, Iasonos A, Mironov S, Scattergood J, Donat SM, et al. Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract. Urology. 2007;69:255-9.
53. Fortuny J, Kogevinas M, Chang-Claude J, Gonzalez CA, Hours M, et al. Tobacco, occupation and non-transitional-cell carcinoma of the bladder: an international case-control study. Int J Cancer. 1999;80:44-6.
54. Vakar-Lopez F, Abrams J. Basaloid squamous cell carcinoma occurring in the urinary bladder. Arch Pathol Lab Med. 2000;124:455-9.
55. Roy S, Smith MA, Cieply KM, Acquafondata MB, Parwani AV. Primary bladder adenocarcinoma versus metastatic colorectal adenocarcinoma: a persisting diagnostic challenge. Diagn Pathol. 2012;7:151.
56. Urquidi V, Rosser CJ, Goodison S. Molecular diagnostic trends in urological cancer: biomarkers for non-invasive diagnosis. Curr Med Chem. 2012;19:3653-63.
57. Yun SJ, Jeong P, Kim WT, Kim TH, Lee YS, et al. Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer. Int J Oncol. 2012;41:1871-8.
58. Di Martino MT, Gulla A, Gallo Cantafio ME, Altomare E, Amodio N, et al. In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells. PLoS One. 2014;9:e89659.
59. Di Martino MT, Gulla A, Cantafio ME, Lionetti M, Leone E, et al. In vitro and in vivo antitumor activity of miR-221/222 inhibitors in multiple myeloma. Oncotarget. 2013;4:242-55.
60. Gulla A, Di Martino MT, Gallo Cantafio ME, Morelli E, Amodio N, et al. A 13 mer LNA-imiR-221 inhibitor restores drug sensitivity in melphalan-refractory multiple myeloma cells. Clin Cancer Res. 2016;22:1222.
61. Felli N, Fontana L, Pelosi E, Botta R, Bonci D, et al. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci U S A. 2005;102:18081-6.
62. Nassirpour R, Mehta PP, Baxi SM, Yin MJ. miR-221 promotes tumorigenesis in human triple negative breast cancer cells. PLoS One. 2013;8:e62170.
63. Stinson S, Lackner MR, Adai AT, Yu N, Kim HJ, et al. TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer. Sci Signal. 2011;4:ra41.
64. Howe EN, Cochrane DR, Richer JK. The miR-200 and miR-221/222 microRNA families: opposing effects on epithelial identity. J Mammary Gland Biol Neoplasia. 2012;17:65-77.
65. Fornari F, Gramantieri L, Ferracin M, Veronese A, Sabbioni S, et al. MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene. 2008;27:5651-61.
66. Amodio N, Rossi M, Raimondi L, Pitari MR, Botta C, et al. miR-29 s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies. Oncotarget. 2015;6: 12837-61.
67. Amodio N, Di Martino MT, Neri A, Tagliaferri P, Tassone P. Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma. Expert Opin Biol Ther. 2013;13 Suppl 1:S125-37.
68. Amodio N, Bellizzi D, Leotta M, Raimondi L, Biamonte L, et al. miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells. Cell Cycle. 2013;12:3650-62.
69. Calderaro J, Rebouissou S, de Koning L, Masmoudi A, Herault A, et al. PI3K/AKT pathway activation in bladder carcinogenesis. Int J Cancer. 2014;134:1776-84.
70. Neuzillet Y, Paoletti X, Ouerhani S, Mongiat-Artus P, Soliman H, et al. A meta-analysis of the relationship between FGFR3 and TP53 mutations in bladder cancer. PLoS One. 2012;7:e48993.
71. Billerey C, Chopin D, Aubriot-Lorton MH, Ricol D, Gil Diez de Medina S, et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol. 2001;158:1955-9.
72. Knowles MA. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis. 2006;27:361-73.
73. Kent OA, Chivukula RR, Mullendore M, Wentzel EA, Feldmann G, et al. Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. Genes Dev. 2010;24:2754-9.
74. Fendler A, Stephan C, Yousef GM, Jung K. MicroRNAs as regulators of signal transduction in urological tumors. Clin Chem. 2011;57:954-68.
75. Hansel DE, Platt E, Orloff M, Harwalker J, Sethu S, et al. Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma. Am J Pathol. 2010;176:3062-72.
76. Morelli E, Leone E, Cantafio ME, Di Martino MT, Amodio N, et al. Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo. Leukemia. 2015;29:2173-83.
77. Wu Q, Yang Z, An Y, Hu H, Yin J, et al. MiR-19a/b modulate the metastasis of gastric cancer cells by targeting the tumour suppressor MXD1. Cell Death Dis. 2014;5:e1144.
78. Olive V, Bennett MJ, Walker JC, Ma C, Jiang I, et al. miR-19 is a key oncogenic component of mir-17-92. Genes Dev. 2009;23:2839-49.
79. Ye H, Liu X, Lv M, Wu Y, Kuang S, et al. MicroRNA and transcription factor co-regulatory network analysis reveals miR-19 inhibits CYLD in T-cell acute lymphoblastic leukemia. Nucleic Acids Res. 2012;40:5201-14.
80. Scheffer AR, Holdenrieder S, Kristiansen G, von Ruecker A, Muller SC, et al. Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer? World J Urol. 2014;32:353-8.
81. Lee H, Jun SY, Lee YS, Lee HJ, Lee WS, et al. Expression of miRNAs and ZEB1 and ZEB2 correlates with histopathological grade in papillary urothelial tumors of the urinary bladder. Virchows Arch. 2014;464:213-20.
82. Xie P, Xu F, Cheng W, Gao J, Zhang Z, et al. Infiltration related miRNAs in bladder urothelial carcinoma. J Huazhong Univ Sci Technolog Med Sci. 2012;32:576-80.
83. Wszolek MF, Rieger-Christ KM, Kenney PA, Gould JJ, Silva Neto B, et al. A MicroRNA expression profile defining the invasive bladder tumor phenotype. Urol Oncol. 2011;29(794-801):e791.
84. Song T, Xia W, Shao N, Zhang X, Wang C, et al. Differential miRNA expression profiles in bladder urothelial carcinomas. Asian Pac J Cancer Prev. 2010;11:905-11.
85. Raimondi L, Amodio N, Di Martino MT, Altomare E, Leotta M, et al. Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity. Oncotarget. 2014;5:3039-54.
86. Adam L, Zhong M, Choi W, Qi W, Nicoloso M, et al. miR-200 expression regulates epithelial- to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res. 2009;15:5060-72.
87. Iwatsuki M, Mimori K, Yokobori T, Ishi H, Beppu T, et al. Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci. 2010;101:293-9.
88. Cannistraci A, Di Pace AL, De Maria R, Bonci D. MicroRNA as new tools for prostate cancer risk assessment and therapeutic intervention: results from clinical data set and patients’ samples. Biomed Res Int. 2014;2014:146170.
89. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 2006;103(7): 2257-61.
90. Kim WT, Kim WJ. MicroRNAs in prostate cancer. Prostate Int. 2013;1:3-9.
91. Wan Y, Zeng ZC, Xi M, Wan S, Hua W, et al. Dysregulated microRNA-224/apelin axis associated with aggressive progression and poor prognosis in patients with prostate cancer. Hum Pathol. 2015;46:295-303.
92. Zhang HL, Qin XJ, Cao DL, Zhu Y, Yao XD, et al. An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions. Asian J Androl. 2013;15:231-5.
93. Wen J, Li R, Wen X, Chou G, Lu J, et al. Dysregulation of cell cycle related genes and microRNAs distinguish the low- from high-risk of prostate cancer. Diagn Pathol. 2014;9:156.
94. Bryant RJ, Pawlowski T, Catto JW, Marsden G, Vessella RL, et al. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer. 2012;106:768-74.
95. Wang L, Yu J, Xu J, Zheng C, Li X, et al. The analysis of microRNA-34 family expression in human cancer studies comparing cancer tissues with corresponding pericarcinous tissues. Gene. 2015;554:1-8.
96. Cosco D, Cilurzo F, Maiuolo J, Federico C, Di Martino MT, et al. Delivery of miR-34a by chitosan/PLGA nanoplexes for the anticancer treatment of multiple myeloma. Sci Rep. 2015;5:17579.
97. Misso G, Di Martino MT, De Rosa G, Farooqi AA, Lombardi A, et al. Mir-34: a new weapon against cancer? Mol Ther Nucleic Acids. 2014;3:e194.
98. Scognamiglio I, Di Martino MT, Campani V, Virgilio A, Galeone A, et al. Transferrinconjugated SNALPs encapsulating 2′-O-methylated miR-34a for the treatment of multiple myeloma. Biomed Res Int. 2014;2014:217365.
99. Di Martino MT, Campani V, Misso G, Gallo Cantafio ME, Gulla A, et al. In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma. PLoS One. 2014;9:e90005.
100. Di Martino MT, Leone E, Amodio N, Foresta U, Lionetti M, et al. Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res. 2012;18:6260-70.
101. Marra M, Salzano G, Leonetti C, Tassone P, Scarsella M, et al. Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes. Nanomedicine. 2011;7:955-64.
102. Marra M, Salzano G, Leonetti C, Porru M, Franco R, et al. New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study. Biotechnol Adv. 2012;30:302-9.
103. Li M, Wang Y, Song Y, Bu R, Yin B, et al. MicroRNAs in renal cell carcinoma: a systematic review of clinical implications (Review). Oncol Rep. 2015;33:1571-8.
104. Yang FQ, Zhang HM, Chen SJ, Yan Y, Zheng JH. MiR-506 is down-regulated in clear cell renal cell carcinoma and inhibits cell growth and metastasis via targeting FLOT1. PLoS One. 2015;10:e0120258.
105. Junker K, Ficarra V, Kwon ED, Leibovich BC, Thompson RH, et al. Potential role of genetic markers in the management of kidney cancer. Eur Urol. 2013;63:333-40.
106. Zhao X, Zhao Z, Xu W, Hou J, Du X. Down-regulation of miR-497 is associated with poor prognosis in renal cancer. Int J Clin Exp Pathol. 2015;8:758-64.
107. Ma L, Qu L. The function of microRNAs in renal development and pathophysiology. J Genet Genomics. 2013;40:143-52.